Fig. 2From: Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumorsTime to event outcomes for the primary efficacy population and the overall study population. a Duration of response, assessed by the blinded independent review committee. b Overall survivalBack to article page